ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cardiac - Pharmacology

September 20, 2022
Plasma metabolomic profiles were examined to determine differences in social determinants of health between Black and white women. This observational study paves the groundwork for further investigation of social disparity in atheromatous disease.
April 19, 2022
Interesting manuscript on the immunology of coronary atheroma, with tanslational potential in therapies and prevention of ischaemic heart disease.
April 5, 2022
A brief but comprehensive editorial on nuances of the links between atrial fibrillation and heart failure, apropos a trial we have commented recently on, by the Johns Hopkins team that develops the calmodulin-dependent protein kinase II inhibitor molecules   
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
November 9, 2021
A good-size Terumo-sponsored RCT that is set to impact on decisions to discontinue DAPT early after PCI with absorbable stent, a change that will somehow decrease the surgical risk of bleeding in the event of salvage CABG. 
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
February 21, 2021
An editorial that may herald the decrease in aspirinization and the rise of ticagrelor monotherapy in Percutaneous stenting of coronary arteries.
November 28, 2020
A large RCT with results somewhat supportive of considering a NOAC in the place of warfarin for post operative surgical patients. The study will be weighed against healthcare economical aspects.
November 17, 2020
A latge RCT of the first myosin inhibitor in severe chronic heart failure: somewhat difficult to interpret results, as deaths were slightly higher in the intervention group while there was no 'significant' benefit in cardiovascular deaths.
August 18, 2020
A review that may affect pharma strategy in the immediate future.

Pages